Roka Bioscience, Inc. (ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced that it has entered into a securities purchase agreement in connection with a private placement. Upon the closing of the private placement, Roka will receive gross proceeds of approximately $22.5 million resulting from the sale of approximately 22,500 shares of the Company's Series A Preferred Stock. Each share of Series A Preferred Stock is convertible into approximately 1,428 shares of the Company's common stock, which is equivalent to a purchase price of $0.70 per common share, or an aggregate of approximately 32,143,000, subject to customary adjustments and certain issuance limitations. The purchasers will receive a five-year warrant to purchase approximately 1,428 shares of the Company's common stock, or an aggregate of approximately 32,143,000, at an exercise price of $0.70 per share for each share of Series A Preferred Stock purchased.

About Roka Bioscience

Roka Bioscience, Inc. is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas® Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. For more information, visit http://www.rokabio.com.